Cross-trading's deadline, an approval built on another approval, and 18.5 million tickets — October 13–19, 2026
A sourced digest of the twenty-one SEC, FDA, and FTC developments from October 13–19, 2026, with the parties, procedural status, money at issue, and the deadlines to calendar.
The week of October 13–19, 2026 produced twenty-one items across the three agencies: nine from the SEC, eight from the FDA, and four from the FTC.
The SEC published no new rulemaking of its own this week. Its cross-trading proposal, the lead item last week, reached the Federal Register on October 15, which starts the sixty-day comment period. The rest was enforcement and one advisory-committee meeting: three individual bars, a revoked registration, two distribution proceedings and final judgments over a phony bid for Virgin Orbit.
The FDA expanded Anktiva into a bladder-cancer population the drug was never tested in directly, and opened a rare-disease framework that would rewrite how much evidence small-population developers have to produce. It also finalised a rule letting standardized foods use salt substitutes.
The FTC sued a ticket broker that bought 18.5 million tickets by circumventing purchase limits, sued a company selling sextortion "recovery" services it did not deliver, moved to hold Martin Shkreli in contempt, and sent $9.8 million to consumers harmed by fraud on Walmart's wire-transfer service.
At a glance
| Agency | Development | Status or amount | Next action |
|---|---|---|---|
| SEC | Cross-trading rule proposal published in the Federal Register (Oct. 15) | Release No. IC-36358, File No. S7-2026-36; would widen eligible securities, modernise the rule's conditions and require aggregated reporting on Form N-PORT and Form N-MFP | Comments close December 14, 2026. 1 |
| SEC | Matthew Brown and Matthew Brown Companies, LLC (reported Oct. 13) | Final judgments entered September 27 over a bogus $200 million offer for Virgin Orbit; $236,451 penalty against Brown and conduct bars against both | Litigation concluded; the money now has to be collected. 2 |
| SEC | John Arthur Hanratty, attorney and former chief compliance officer (Oct. 13) | Industry bar and immediate suspension from practising before the Commission, after convictions for wire fraud and bank fraud; 366 days' imprisonment imposed May 26, 2026 | Bar in force; no court approval needed. 3 |
| SEC | David Kushner and La Mancha Funding Corp. (Oct. 13) | Adviser bar, on allegations that $2.14 million was misappropriated from investors; Kushner pleaded guilty in September 2025 to New York grand-larceny counts | Bar in force; sentencing on the state counts is separate. 4 |
| SEC | Michael D. Williams, CMI Capital LLC (Oct. 15) | Adviser bar; raised at least $860,000 from 18 investors across two funds between October 2023 and August 2024 | Bar in force; the civil action continues in the Southern District of Florida. 5 |
| SEC | Silver Star Properties REIT, Inc. (Oct. 14) | Registration revoked under Section 12(j) effective October 15; no periodic report filed since the quarter ended September 30, 2023 | Holders should confirm how custodians value and transfer SLVSQ. 6 |
| SEC | Tai Mo Shan Limited (Oct. 15) | Time extended to approve or disapprove a plan of distribution; eight comments came in on the August 20 proposal | Commission decision on the plan; no date set. 7 |
| SEC | Raymond Lawrence Lent, Putney Financial Group (Oct. 15) | Proposed plan of distribution published for comment, File No. 3-21943 | Comments run thirty days from October 15, so November 14, 2026. 8 |
| SEC | Small Business Capital Formation Advisory Committee (Oct. 14) | Meeting on October 27 at 10 a.m. on IPO modernisation and Regulation Crowdfunding | Attend in Washington or by webcast. 9 |
| FDA | Anktiva (nogapendekin alfa inbakicept-pmln) with BCG (Oct. 14) | First approval for BCG-unresponsive, high-grade papillary-only bladder cancer, granted to Altor BioScience; the decision rests on evidence from the earlier carcinoma-in-situ approval | Clinicians gain an option after BCG failure; sponsors await the final guidance on that extrapolation. 10 |
| FDA | Rare Disease Framework Initiative (Oct. 14) | White paper and public docket, FDA-2026-N-12214; about 5% of rare conditions have an approved treatment | Public meeting October 28; comments close December 11, 2026. 11 |
| FDA | Salt substitutes in standardized foods (Oct. 13) | Final rule amending standards of identity that name salt as a required or optional ingredient | Review formulations and labels against the amended standards. 12 |
| FDA | Chromium propionate in poultry feed (Oct. 14) | Final rule allowing chromium propionate for laying hens and breeder chickens, on a petition from Kemin Industries | Comments close November 13, 2026. 13 |
| FDA | Four emergency use authorisations for New World screwworm (Oct. 15) | Products from Elanco, Zoetis, Bimeda and Sergeant's, for prevention or treatment in livestock and pets | Authorisations carry conditions; check the species and dosing limits in each. 14 |
| FDA | Warning letters posted October 13 | Ten letters with issue dates from July 22 to October 6, including Silgan Dispensing Systems, Hanlim Pharm, Lovelace Biomedical Research Institute and Eurofins SF Analytical Laboratories | Screen supplier and contractor lists against the ten names. 15 |
| FDA | Tobacco Products Scientific Advisory Committee (Oct. 15) | Two voting vacancies for physicians, dentists, scientists or health professionals | Nominate through docket FDA-2026-N-11624; the notice sets no closing date. 16 |
| FDA | eCTD 4.0 forward compatibility (Oct. 16) | CDER and CBER will support forward-compatible submissions under eCTD v3.2.2 and v4.0 | Submitters should check that their publishing toolchain carries the newer standard. 17 |
| FTC | REPS & Company Inc. and three executives (Oct. 15) | Suit filed by the Department of Justice in the Southern District of California under the BOTS Act; more than 18.5 million tickets bought across at least 83,500 events, and at least $120.8 million in profit | Civil penalties to be decided by the court. 18 |
| FTC | Digital Forensics Corporation LLC and Dmitry Belkin (Oct. 13) | Suit in the Northern District of Ohio; consumers paid at least $60 million for sextortion assistance that was not provided; a temporary restraining order is in place | Preliminary injunction next; refund exposure runs to every paying customer. 19 |
| FTC | Martin Shkreli (Oct. 13) | Contempt motion by the FTC and seven states over pharmaceutical-stock trading and broadcasts; seeks his trading profits plus escalating sanctions | Hearing on the order to show cause. 20 |
| FTC | Walmart redress (Oct. 15) | More than $9.8 million to 65,022 consumers harmed by fraud carried out over Walmart's wire-transfer service | Cheques cash within 90 days; questions go to Rust Consulting. 21 |
SEC
The cross-trading clock starts
The Commission's cross-trading proposal was published in the Federal Register on October 15 as Release No. IC-36358, under File No. S7-2026-36. That publication is what starts the comment period, and comments close December 14, 2026. 1
The proposal amends the rule under the Investment Company Act that lets a registered fund buy and sell securities with certain affiliates. It would widen the categories of securities eligible for those trades, modernise the conditions attached to them, and require funds to report trading activity and cross trades in aggregate on Form N-PORT and Form N-MFP. 1
Two groups carry the work. Fund advisers that rely on affiliated trades need to track the publication date and decide whether to comment. Fund accounting and compliance teams would have to build the aggregate reporting into existing Form N-PORT and Form N-MFP processes if the rule is adopted.
The crypto-asset custody proposal the Commission issued on October 1 still has no Federal Register publication, so its comment clock has not started.
Three men barred from the industry
John Arthur Hanratty was a New York-licensed attorney who had served as chief compliance officer and general counsel at a registered broker-dealer, and who ran two municipal-tax-lien funds with forty-three investors at Ebury Street Capital. He was convicted on August 4, 2025 of wire fraud, bank fraud and two counts of monetary transactions in criminally derived property. 3
Hanratty was sentenced on May 26, 2026 to 366 days in prison on each count, running concurrently, and two years of supervised release.
The conduct ran from 2017 into 2021 and involved false statements to a specialty finance company owned by an insured bank, and about $920,000 moved from the proceeds. The Commission suspended him from practising before it under Rule 102(e)(2) and barred him from association with a broker, dealer, investment adviser or similar firm. 3
David Kushner was president and sole owner of La Mancha Funding Corp. From September 2018 to April 2021, the Commission alleges, he and the firm misappropriated at least $2.14 million from investors who bought membership interests in limited liability companies. He pleaded guilty on September 16, 2025 to New York grand-larceny counts and a scheme-to-defraud count. 4
Michael D. Williams, who is 33 and lives in St. Lucie, Florida, founded and ran CMI Capital, LLC. Between October 2023 and August 2024 he raised at least $860,000 from at least eighteen investors in two funds, the Commission found, on misstatements about how the money would be used, the funds' portfolio values and the past performance and risks of the trading strategy. 5
All three consented. The Kushner and Williams orders rest on civil or criminal findings already made; Hanratty's suspension follows directly from the felony conviction. For a compliance team, the practical point is screening: an industry bar applies to association with a covered firm, and each of these orders is now a matter of record for anyone running background checks on supervised persons.
One registration revoked, two distribution plans
The Commission revoked the registration of Silver Star Properties REIT, Inc. on October 14, effective October 15. The Houston company, whose common stock is quoted on OTC Link under the symbol SLVSQ, had filed no periodic report since the quarter ended September 30, 2023, which put it in violation of Section 13(a) and the rules under it. 6
Revocation under Section 12(j) is the Commission's remedy for an issuer that stops reporting. The order recites the statutory consequence: no exchange member, broker or dealer may use the mails or interstate commerce to effect a transaction in a security whose registration has been revoked. Holders of SLVSQ and anyone holding it as collateral should establish how their custodian will value and transfer it from here.
The two distribution matters are further along and concern money already collected.
In the Tai Mo Shan Limited proceeding, the Commission extended its time to approve or disapprove a plan of distribution. The proposed plan was published on August 20, comments closed on September 19, and eight comments came in, one of them late. Thirty days from the close of comment would have run out on October 19. 7
In the Raymond Lawrence Lent matter, the Commission published a proposed plan of distribution and opened it for comment, in File No. 3-21943. Comments run thirty days from the October 15 notice, which puts the deadline at November 14, 2026. 8
Final judgments over a bid that was never real
Matthew Brown and Matthew Brown Companies, LLC submitted and publicly promoted an offer to invest $200 million in Virgin Orbit Holdings, then a Nasdaq-listed company trading as VORB. The offer was bogus.
The Commission sued in the Northern District of Texas in June 2024, won summary judgment on liability in August 2025, and on September 27 of this year obtained final judgments against both defendants. 2
The judgments permanently enjoin both from violating the antifraud provisions. Brown is barred from participating in the issuance, purchase, offer or sale of any security except for his own account, barred from serving as an officer or director of a public company, and ordered to pay a $236,451 civil penalty. The Commission's release, published October 13, says the litigation is concluded. 2
The penalty is a fraction of the offer the case was built on. What the case establishes is that announcing a financing commitment can itself be the violation when the commitment is fabricated and the announcement is meant to move a public company's shares.
Also on the SEC docket
The Small Business Capital Formation Advisory Committee meets on October 27 at 10 a.m. at the Commission's headquarters, with a live stream. The morning covers IPO modernisation: the offering process, communications rules during an IPO, and analyst coverage and support. The afternoon covers Regulation Crowdfunding, including its current framework, its results so far and possible changes. 9
The committee advises and recommends. It does not propose rules, so the meeting is a signal of where small-capital policy discussion is heading rather than a step in a rulemaking.
FDA
An approval built out of another approval
On October 14 the FDA expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), given with BCG, to adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG. It is the first treatment approved specifically for that population. The application was granted to Altor BioScience, LLC. 10
The approval rests on no trial in that population. Anktiva was already approved for carcinoma in situ, a flat, always-high-grade form of the same non-muscle-invasive disease.
That trial enrolled 77 adults; 62% had a complete response, 58% of those held it for at least twelve months and 40% for at least twenty-four. The agency then used clinical and laboratory evidence that carcinoma in situ and high-grade papillary tumours often occur together, are hard to tell apart under a microscope and carry similar risk of returning. 10
The regimen is weekly for six weeks through a catheter, with further treatment based on response, for up to 37 months. Reported adverse reactions include painful and frequent urination, blood in the urine, urinary tract infections, muscle and joint pain, chills and fever. The label warns that delaying removal of part or all of the bladder can let the cancer spread. 10
The FDA is working to finalise its draft guidance on developing drugs for BCG-unresponsive non-muscle-invasive bladder cancer, which is meant to discuss using carcinoma-in-situ evidence to support approvals in papillary-only disease. Sponsors with a candidate in that space have both the precedent and, shortly, a written route through it. 10
ImmunityBio, Inc., the publicly traded parent of Altor BioScience, is the one company in this issue whose own product was the subject of a decision. IBRX closed at $9.91 on October 14, up 1.1% from $9.80 the day before, on 30.2 million shares against a daily average of about 15.1 million over the preceding month.
It closed at $10.00 on October 15 and $9.18 on October 16. 22
Rare diseases get their own evidence framework
On October 14 the FDA announced the Rare Disease Framework Initiative, with a white paper setting out why the agency wants a different review framework for drugs and biologics aimed at rare diseases. The premise is arithmetic: only about 5% of rare conditions have an approved treatment. 23
The initiative commits the agency to six things: clearer and more predictable decisions through tailored guidance; the patient voice at defined points in development and review; more use of outside expertise; shared resources and training on rare-disease review; risk-based approaches to chemistry, manufacturing and controls review and to pre-approval inspections; and acceptance of novel methods and statistical approaches. 23
Two dates follow. A public meeting is set for October 28 at the FDA's White Oak campus, run with the Reagan-Udall Foundation, and the agency opened docket FDA-2026-N-12214 for written input, with comments closing December 11, 2026. 11
The agency says further input will come through sector-specific roundtables and additional requests for information, and that the result could include new or revised guidance, changes to regulations, staff training and organisational change. 23
For a sponsor, the sequence matters more than the language. Guidance is the fastest lever and regulations are the slowest, so the near-term changes to watch are the tailored guidance documents rather than the framework itself. The October 28 meeting is where the agency will hear which requirements sponsors consider least suited to small populations.
Salt substitutes move into the standards of identity
A final rule published on October 13 amends the FDA's standards of identity — the regulations that define what a given food must contain to be sold under its name — where those standards name salt as a required or optional ingredient. Manufacturers may now use salt substitutes in those foods. 12
The rule is in Docket No. FDA-2022-N-2226, carries no comment period, and takes effect on December 14, 2026. The agency's stated purpose is sodium reduction, and it frames the change as flexibility for reformulation while keeping the basic character of the standardized food intact. 12
Food manufacturers that have held back reformulation because a standard required salt now have room to move. Labels and ingredient declarations still have to match what is in the product.
Also on the FDA docket
A final rule published October 14 allows chromium propionate as a source of chromium in feed for laying hens and breeder chickens, answering a petition from Kemin Industries. Comments close November 13, 2026. 13
On October 15 the agency announced four emergency use authorisations for animal products against New World screwworm: an Elanco product applied around wounds to prevent infestation in sheep, cattle, goats, swine, camelids and several wildlife species; a Zoetis product to treat infestations in dogs and puppies; a Bimeda product to prevent infestation in cattle; and a Sergeant's product for treatment and prevention in dogs, puppies, cats and kittens.
The authorisations follow the August 18, 2025 determination and declaration by the Secretary of Health and Human Services. 14
Ten warning letters were posted on October 13, with issue dates running from July 22 to October 6. They cover current good manufacturing practice findings at Silgan Dispensing Systems, Hanlim Pharm Co. and Jiangmen Shuizirun Sanitary Articles; good laboratory practice findings at Lovelace Biomedical Research Institute; insanitary-conditions and seafood HACCP findings at RDM Express Inc. and Ocean Pride Seafood, Inc.; foreign supplier verification findings at Moda Food LLC and Ruukoo International Food Market Inc.
An adulterated new animal drug finding at John & Nicole Santos Dairy; and CGMP findings at Eurofins SF Analytical Laboratories, Inc., a contract testing laboratory. 15
The FDA is recruiting two voting members for the Tobacco Products Scientific Advisory Committee, seeking physicians, dentists, scientists or health care professionals in oncology, pulmonology, cardiology, toxicology, pharmacology, addiction or engineering. Nominations go to docket FDA-2026-N-11624 and the notice sets no closing date. 16
CDER and CBER said on October 16 that they will support forward compatibility for electronic submissions built to eCTD version 4.0, alongside continued support for version 3.2.2. Regulatory operations teams that have not tested a v4.0 toolchain now have a dated signal to do it. 17
FTC
Eighteen and a half million tickets
The Department of Justice filed suit on October 15 on the FTC's referral against REPS & Company Inc., a ticket broker, and three of its executives: chief executive Ryan Pancheri, president Brian Archibald and chief operating officer Nicholas Totagrande.
The complaint, filed in the Southern District of California, alleges violations of the Better Online Ticket Sales Act, which makes it illegal to circumvent security measures a ticket issuer uses to enforce purchase limits. 18
The scale in the complaint is the story. Since 2022, the FTC alleges, REPS bought more than eight tickets for at least 83,500 events, spent more than $1.3 billion to amass more than 18.5 million tickets, and made at least $120.8 million reselling them.
At one Beyoncé Renaissance tour concert in Kansas City in 2023, the company used 1,300 accounts to buy 7,624 tickets and made $833,000. 18
The methods alleged are operational rather than technical: thousands of purchasing accounts opened in other people's names, addresses or phone numbers with their agreement, virtual cards and phone numbers the company controlled, proxy services and multi-session browsers, and staff — mostly in the Philippines — who adjusted account details after issuers blocked purchases. 18
The Commission voted 2-0 to refer the complaint. Civil penalties are for the court to set. Ticket issuers named in the complaint as operating the controls — Ticketmaster and AXS — and resale platforms that list inventory from brokers like this one are the businesses most directly exposed to what the case establishes.
A recovery service that recovered nothing
On October 13 the FTC sued Digital Forensics Corporation LLC, its owner Dmitry Belkin and eleven affiliated companies, and obtained a temporary restraining order. The complaint, filed in the Northern District of Ohio, alleges that the operation took at least $60 million from victims of sextortion — people threatened with the publication of an intimate image — by promising to identify the extortionist and end the attack. 19
The sales structure has two stages. A "Phase 1" package costing between $1,499 and $20,000 was to include locating the extortionist, communicating with them, producing an investigative report and reporting to law enforcement. Customers were then pushed into "Phase 2" for ongoing monitoring. The FTC alleges the work often amounted to blocking the extortionist on the victim's own accounts, creating fake chat transcripts and inventing investigative detail. 24
Two alleged practices reach beyond the victims. The company suppressed negative reviews and generated positive ones — written by employees in India, bought from Uber drivers who had never used the service, and extracted from customers before any work was done. The complaint charges violations of the FTC Act, the Telemarketing Sales Rule, the Reviews and Testimonials Rule and the Gramm-Leach-Bliley Act. 19
The review counts are the transferable risk. Any business that buys reviews, gates a review behind a service milestone or uses staff to seed ratings now has a recent complaint applying the Reviews and Testimonials Rule to exactly those practices.
Shkreli, back before a judge
The FTC and seven states asked the Southern District of New York on October 13 to hold Martin Shkreli in civil contempt for violating the 2022 order that banned him from the pharmaceutical industry for life. The motion alleges that since his release from prison in May 2022 he has traded pharmaceutical stocks publicly and broadcast his views on the companies whose shares he held. 20
The 2022 order followed a trial over Daraprim, the toxoplasmosis drug, in which the court found that Shkreli had organised a scheme to protect a monopoly. The order barred him from acquiring or holding an ownership interest in a pharmaceutical company and from acting to influence or control the management or business of one. 20
The motion cites livestreams on YouTube, X and Reddit in which, it alleges, he traded pharmaceutical stocks while telling viewers how to trade biotech, and ran campaigns shorting companies on predictions that their trials would fail.
Remedies sought are disgorgement of trading profits with prejudgment interest and no offset for losses, plus escalating penalties that could include incarceration. The Commission vote was 1-0, with Chairman Andrew N. Ferguson recused and Commissioner Mark R. Meador issuing a statement. 20
The Walmart distribution
The FTC is sending more than $9.8 million to 65,022 consumers harmed by scammers who moved hundreds of millions of dollars through Walmart's wire-transfer services. Cheques are being mailed and must be cashed within 90 days; Rust Consulting Inc. is administering the payments. 21
The liability was set in June 2025, when Walmart settled charges that it failed to implement effective anti-fraud policies, train employees and warn customers about fraud on money transfers. Under that settlement the company must act to detect and prevent fraud-induced transfers.
This week's news is the payout. The compliance reading is the control standard: a money-transfer provider is answerable for the fraud controls on its own rail. 21
Deadlines to calendar
| Date | Item | Action |
|---|---|---|
| Oct. 22, 2026 | FTC proposed consent order with FleetCor Technologies | Comment. 25 |
| Oct. 27, 2026 | SEC Small Business Capital Formation Advisory Committee meeting | Attend, in Washington or by webcast. 9 |
| Oct. 28, 2026 | FDA public meeting on the Rare Disease Framework Initiative | Attend or request to speak. 11 |
| Oct. 30, 2026 | FTC petition for rulemaking of Malik Tony Singleton | Comment. 26 |
| Nov. 9, 2026 | FDA request for information on deceased donor islet cells | Comment. 27 |
| Nov. 13, 2026 | FDA final rule on chromium propionate in poultry feed | Comment. 13 |
| Nov. 14, 2026 | SEC proposed plan of distribution in the Raymond Lawrence Lent matter | Comment. 8 |
| Nov. 15, 2026 | FDA advisory committee consumer representative nominations | Nominate, for first consideration. 28 |
| Nov. 20, 2026 | FDA request for information on ibogaine trial design | Comment. 29 |
| Nov. 23, 2026 | FDA draft guidance on food traceability enforcement policy | Comment. 30 |
| Nov. 24, 2026 | FDA draft guidance on robotically-assisted surgical devices | Comment. 31 |
| Nov. 25, 2026 | FDA public meeting on reauthorisation of the Biosimilar User Fee Act | Comment or attend. 32 |
| Nov. 30, 2026 | FTC Rule on Impersonation of Government and Businesses | Comment. 33 |
| Nov. 30, 2026 | FDA advisory committee scientific and technical member nominations | Nominate, for first consideration. 28 |
| Dec. 4, 2026 | SEC private-market retailisation proposals and accredited-investor designation notices | Comment. 34 |
| Dec. 6, 2026 | FDA public meeting on lot-level food traceability | Comment or attend. 35 |
| Dec. 7, 2026 | FTC and USDA agricultural equipment request for information | Comment. 36 |
| Dec. 7, 2026 | FDA direct final rule on nonclinical testing terminology | Comment on the companion proposed rule. 37 |
| Dec. 11, 2026 | FDA docket on the Rare Disease Framework Initiative | Comment. 11 |
| Dec. 14, 2026 | SEC cross-trading proposal | Comment. 1 |
Where these matters stand
The SEC's week was almost entirely consequences. Three individuals are now barred, one issuer's registration is revoked, one set of final judgments closes a two-year case, and two distribution proceedings moved toward paying out money already collected. Only the cross-trading proposal is prospective, and its practical work is a comment letter or an internal decision about how to build aggregate reporting into Form N-PORT and Form N-MFP.
The two FDA policy items turn on the same question: how much evidence is enough when the patient population is small. Anktiva answers it by carrying trial results from one presentation of a cancer to another. The rare disease initiative asks whether that kind of extrapolation can be made systematic across conditions.
The salt rule belongs to a different FDA line entirely — composition standards rather than evidence standards — and its effect is felt by food manufacturers rather than drug sponsors.
Three of the four FTC matters involve a company selling something it controlled: access to tickets, a recovery service, a wire-transfer rail. The fourth is order enforcement against a defendant who was banned from an industry and kept trading in it.
The operational lessons are narrow and checkable: ticket-purchase and account-creation controls at any resale business, review-generation practices anywhere reviews drive sales, fraud monitoring on payment rails, and a screen for industry bars when hiring or onboarding.
Only one company named this week trades publicly on news about its own product: ImmunityBio, whose stock moved on the approval day and again later in the week. The rest are private firms and individual respondents, and the SEC's distribution matters affect fund investors rather than a listed issuer.
References
- 1Investment Company Cross Trading
federalregister.gov
- 2
- 3
- 4Order as to David Kushner
sec.gov
- 5
- 6
- 7
- 8
- 9
- 10
- 11Fit-for-purpose Rare Disease Framework Initiative
federalregister.gov
- 12Use of salt substitutes to reduce the sodium content in standardized foods
federalregister.gov
- 13
- 14Authorization of emergency use for four animal drugs for New World screwworm
federalregister.gov
- 15FDA warning letters index
fda.gov
- 16
- 17
- 18
- 19
- 20
- 21
- 22ImmunityBio daily closes, September 17 to October 16, 2026 (Yahoo Finance)
query1.finance.yahoo.com
- 23
- 24
- 25FleetCor Technologies consent order notice
federalregister.gov
- 26Petition for rulemaking of Malik Tony Singleton
federalregister.gov
- 27Improving patient access to deceased donor islet cells
federalregister.gov
- 28
- 29Design and safety considerations for clinical trials involving ibogaine
federalregister.gov
- 30Requirements for additional traceability records for certain foods
federalregister.gov
- 31Robotically-Assisted Surgical Devices draft guidance
federalregister.gov
- 32Reauthorization of the Biosimilar User Fee Act
federalregister.gov
- 33Rule on Impersonation of Government and Businesses
federalregister.gov
- 34Interval Fund Modernization
federalregister.gov
- 35Challenges and solutions in lot-level food traceability
federalregister.gov
- 36
- 37Nonclinical Testing Terminology
federalregister.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.